GL1X · GenesisL1 explorer

Research workbench

Crystal structure of pfcsp peptide 21 with vaccine-elicited human anti-malaria antibody M43.138

Analyse Crystal structure of pfcsp peptide 21 with vaccine-elicited human anti-malaria… in the GL1X research workbench: secondary structure, accessibility, pockets, interfaces, conservation, variants, modifications, peptides, crosslinks and neighbours on the 3D structure.

PDB
7RDA
Type
protein
Length
452 residues
Chains
3
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Circumsporozoite protein; Antibody M43.138 heavy chain; Antibody M43.138 light chain
UniProt
P02893
Pockets
3 · best druggability 0.64

Structure

x-ray diffraction · 3 distinct chains · 8% helix, 51% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
CCircumsporozoite proteinprotein140% helix, 7% strandP02893
HAntibody M43.138 heavy chainprotein22010% helix, 53% strand—
LAntibody M43.138 light chainprotein2187% helix, 52% strand—

Pockets

3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16110.640.7562empty
2500.540.8918empty
3740.390.7815empty

Interfaces

3 interfaces between chains.

  • H–L · 1897 Ų buried · 16 hydrogen bonds · protein-protein
  • C–L · 494 Ų buried · 6 hydrogen bonds · protein-protein
  • C–H · 489 Ų buried · 13 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 4 disulfide (disulfide).

Compared structures

  • 7RDA · Crystal structure of PfCSP peptide 21 with vaccine-elicited human anti-malaria antibody… · the same entry in another collection · chain C against C, TM-score 1.00
  • P02893 · AlphaFold monomer V2.0 prediction for circumsporozoite protein (P02893) · a predicted model of the same protein · chain C against A, TM-score 0.26

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.